Chronic oral rapamycin decreases adiposity, hepatic triglycerides and insulin resistance in male mice fed a diet high in sucrose and saturated fat

What is the central question of this study? Whether chronic oral rapamycin promotes beneficial effects on glucose/lipid metabolism and energy balance when administered to mice with an obesogenic diet rich in saturated fat and sucrose has not been explored. What is the main finding and its importance? Chronic oral rapamycin reduces body weight and fat gain, improves insulin sensitivity and reduces hepatic steatosis when administered to mice with a high‐fat, high‐sucrose diet. In addition, we make the new observation that there appear to be tissue‐specific effects of rapamycin. Although rapamycin appears to impart its effects mainly on visceral adipose tissue, its effects on insulin sensitivity are mediated by subcutaneous adipose tissue.

[1]  S. Kuang,et al.  Adipocyte-specific DKO of Lkb1 and mTOR protects mice against HFD-induced obesity, but results in insulin resistance[S] , 2018, Journal of Lipid Research.

[2]  D. Harrison,et al.  Cardioprotective effects of dietary rapamycin on adult female C57BLKS/J‐Leprdb mice , 2018, Annals of the New York Academy of Sciences.

[3]  S. Collins,et al.  Cardiac natriuretic peptides promote adipose ‘browning’ through mTOR complex-1 , 2018, Molecular metabolism.

[4]  D. Rader,et al.  mTORC1 stimulates phosphatidylcholine synthesis to promote triglyceride secretion , 2017, The Journal of clinical investigation.

[5]  S. Subramanian,et al.  Metabolically distinct weight loss by 10,12 CLA and caloric restriction highlight the importance of subcutaneous white adipose tissue for glucose homeostasis in mice , 2017, PloS one.

[6]  N. Câmara,et al.  mTORC1 inhibition with rapamycin exacerbates adipose tissue inflammation in obese mice and dissociates macrophage phenotype from function. , 2017, Immunobiology.

[7]  Wei Zhang,et al.  Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer’s disease , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  D. Harrison,et al.  Rapamycin treatment benefits glucose metabolism in mouse models of type 2 diabetes , 2016, Aging.

[9]  S. Kuang,et al.  Adipocyte-specific deletion of mTOR inhibits adipose tissue development and causes insulin resistance in mice , 2016, Diabetologia.

[10]  Kalyani V. P. Guntur,et al.  Activation of mTORC1 is essential for β-adrenergic stimulation of adipose browning. , 2016, The Journal of clinical investigation.

[11]  Dudley Lamming,et al.  Rapamycin Blocks Induction of the Thermogenic Program in White Adipose Tissue , 2016, Diabetes.

[12]  S. A. Arriola Apelo,et al.  Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system , 2015, Aging cell.

[13]  Dudley Lamming,et al.  Rapamycin-induced metabolic defects are reversible in both lean and obese mice , 2014, Aging.

[14]  M. Westerterp,et al.  Macrophage mTORC1 disruption reduces inflammation and insulin resistance in obese mice , 2014, Diabetologia.

[15]  P. Froguel,et al.  Beneficial Metabolic Effects of Rapamycin Are Associated with Enhanced Regulatory Cells in Diet-Induced Obese Mice , 2014, PloS one.

[16]  M. Blagosklonny,et al.  Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet , 2014, Aging cell.

[17]  Z. D. Sharp,et al.  Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction , 2014, Aging cell.

[18]  H. Fuchs,et al.  Rapamycin extends murine lifespan but has limited effects on aging. , 2013, The Journal of clinical investigation.

[19]  Yun Shi,et al.  Rapamycin Modulates Markers of Mitochondrial Biogenesis and Fatty Acid Oxidation in the Adipose Tissue of db/db Mice. , 2013, Journal of biochemical and pharmacological research.

[20]  J. Olefsky,et al.  Liver-specific p70 S6 Kinase Depletion Protects against Hepatic Steatosis and Systemic Insulin Resistance* , 2012, The Journal of Biological Chemistry.

[21]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[22]  Dudley Lamming,et al.  Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity , 2012, Science.

[23]  V. Anisimov,et al.  Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice , 2011, Cell cycle.

[24]  Y. Jan,et al.  Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity , 2011, Journal of Molecular Medicine.

[25]  R. de Cabo,et al.  Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. , 2011, The journals of gerontology. Series A, Biological sciences and medical sciences.

[26]  D. Sabatini,et al.  Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. , 2010, Molecular cell.

[27]  Jayanta Debnath,et al.  Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease , 2010, PloS one.

[28]  Y. Deshaies,et al.  Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue , 2010, Diabetes.

[29]  C. Glass,et al.  Macrophages, inflammation, and insulin resistance. , 2010, Annual review of physiology.

[30]  Janet M. Thornton,et al.  Ribosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span , 2009, Science.

[31]  H. Hsu,et al.  Long-term administration of rapamycin reduces adiposity, but impairs glucose tolerance in high-fat diet-fed KK/HlJ mice. , 2009, Basic & clinical pharmacology & toxicology.

[32]  Marco Pahor,et al.  Rapamycin fed late in life extends lifespan in genetically heterogeneous mice , 2009, Nature.

[33]  A. Thomson,et al.  Immunoregulatory functions of mTOR inhibition , 2009, Nature Reviews Immunology.

[34]  Geng-Ruei Chang,et al.  Rapamycin protects against high fat diet-induced obesity in C57BL/6J mice. , 2009, Journal of pharmacological sciences.

[35]  J. Auwerx,et al.  Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. , 2008, Cell metabolism.

[36]  Claudio R. Santos,et al.  SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell Growth , 2008, Cell metabolism.

[37]  H. Meier‐Kriesche,et al.  Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[38]  A. Webster,et al.  Sirolimus is associated with new-onset diabetes in kidney transplant recipients. , 2008, Journal of the American Society of Nephrology : JASN.

[39]  S. Subramanian,et al.  Dietary Cholesterol Worsens Adipose Tissue Macrophage Accumulation and Atherosclerosis in Obese LDL Receptor–Deficient Mice , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[40]  Christophe Magnan,et al.  mTOR Inhibition by Rapamycin Prevents β-Cell Adaptation to Hyperglycemia and Exacerbates the Metabolic State in Type 2 Diabetes , 2008, Diabetes.

[41]  J. Cruzado.  Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors. , 2008, Transplantation reviews.

[42]  V. Mootha,et al.  mTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex , 2007, Nature.

[43]  G. Thomas,et al.  mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. , 2007, Trends in molecular medicine.

[44]  M. Roden,et al.  The Mammalian Target of Rapamycin Pathway Regulates Nutrient-Sensitive Glucose Uptake in Man , 2007, Diabetes.

[45]  C. Tsang,et al.  Targeting mammalian target of rapamycin (mTOR) for health and diseases. , 2007, Drug discovery today.

[46]  J. Romijn,et al.  Sustained activation of the mammalian target of rapamycin nutrient sensing pathway is associated with hepatic insulin resistance, but not with steatosis, in mice , 2006, Diabetologia.

[47]  M. Fernández,et al.  Rapamycin, an mTOR inhibitor, disrupts triglyceride metabolism in guinea pigs. , 2006, Metabolism: clinical and experimental.

[48]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[49]  D. Sabatini,et al.  Growing roles for the mTOR pathway. , 2005, Current opinion in cell biology.

[50]  S. di Paolo,et al.  Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. , 2005, Journal of the American Society of Nephrology : JASN.

[51]  Peter Nowotny,et al.  Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. , 2005, Diabetes.

[52]  A. Marette,et al.  Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. , 2005, Endocrinology.

[53]  Johan Auwerx,et al.  Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity , 2004, Nature.

[54]  C. Ballantyne,et al.  Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients DOI 10.1194/jlr.M100392-JLR200 , 2002, Journal of Lipid Research.

[55]  R. Burcelin,et al.  Hypoinsulinaemia, glucose intolerance and diminished β-cell size in S6K1-deficient mice , 2000, Nature.

[56]  J. Sredy,et al.  Rapamycin prevents the onset of insulin‐dependent diabetes mellitus (IDDM) in NOD mice , 1992, Clinical and experimental immunology.

[57]  J. Folch,et al.  A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.